Neurocrine Biosciences (NBIX) Long-Term Investments (2010 - 2026)

Neurocrine Biosciences' Long-Term Investments history runs 17 years deep, the most recent figure standing at $146.1 million for Q1 2026.

• Quarterly Long-Term Investments rose 55.1% year-over-year to $146.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $146.1 million (up 55.1% YoY) and the FY2025 annual result came in at $1.1 billion, up 751.76% from the prior year.
• Long-Term Investments was $146.1 million for Q1 2026 at Neurocrine Biosciences, down from $1.1 billion in the prior quarter.
• Across five years, Long-Term Investments topped out at $1.1 billion in Q4 2025 and bottomed at $83.8 million in Q2 2022.
• A 5-year average of $320.0 million and a median of $146.1 million in 2026 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2024 — Long-Term Investments plunged 81.85% — and 2025, when it jumped 751.76%.
• Neurocrine Biosciences' Long-Term Investments stood at $299.4 million in 2022, then surged by 129.63% to $687.5 million in 2023, then plunged by 81.85% to $124.8 million in 2024, then jumped by 751.76% to $1.1 billion in 2025, then plunged by 86.26% to $146.1 million in 2026.
• Business Quant data shows NBIX's Long-Term Investments at $146.1 million in Q1 2026, $1.1 billion in Q4 2025, and $118.1 million in Q3 2025.